AstraZeneca doubles Lokelma output with $445m Texas plant expansion

AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to meet increasing demand for hyperkalaemia treatment Lokelma (sodium zirconium cyclosilicate). The near half a billion-dollar expansion at AstraZeneca’s manufacturing facility in Coppell, Texas, adds a new 9,000ft² building, which will house two production lines. The investment will also fund upgrades for drug substance and drug product laboratory testing, along with additional space for ...